Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 3/20 | 0.31 |
| ▸ | MMP2 | P08253 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3835251 | 0.95 | NR1H4 (0.44) | NR1H4ELANECTSD | |
| SCHEMBL3833715 | 0.92 | NR1H4 (0.45) | NR1H4ELANECTSD | |
| SCHEMBL5721660 | 0.91 | NR1H4 (0.45) | NR1H4ELANECTSD | |
| SCHEMBL4665640 | 0.90 | NR1H4 (0.44) | NR1H4ELANECTSD | |
| SCHEMBL5709264 | 0.89 | NR1H4 (0.42) | NR1H4ELANECTSD | |
| SCHEMBL5689568 | 0.89 | NR1H4 (0.42) | NR1H4ELANECTSD | |
| SCHEMBL4617561 | 0.89 | NR1H4 (0.42) | NR1H4ELANECTSD | |
| SCHEMBL6256758 | 0.89 | NR1H4 (0.50) | NR1H4ELANECTSD | |
| SCHEMBL3838373 | 0.89 | NR1H4 (0.50) | NR1H4ELANECTSD | |
| SCHEMBL3836167 | 0.88 | NR1H4 (0.45) | NR1H4ELANECTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1879860-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | Microbia Inc. (US) | 2008-01-23 | — | — | EP | disclosed |
| EP-1877373-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | Microbia, Inc. (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1851197-A2 | PHENYLAZETIDINONE DERIVATIVES | Microbia, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006122186-A2 | 1,4-DIPHENYL-3-HYDROXYALKYL-2-AZETIDINONE DERIVATIVES FOR TREATING HYPERCHOLESTROLEMIA | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006121861-A2 | BIPHENYLAZETIDINONE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
| WO-2006086562-A2 | PHENYLAZETIDINONE DERIVATIVES | MICROBIA, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1610770-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | AstraZeneca AB (SE) | 2006-01-04 | — | — | EP | disclosed |
| EP-1521742-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | AstraZeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004089350-A1 | USE OF AN IBAT INHIBITOR FOR THE TREATMENT OF PROPHYLAXIS OF CONSTIPATION | ASTRAZENECA AB (SE) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004005247-A1 | DIPHENYLAZETIDINONE DERIVATIVES FOR TREATING DISORDERS OF THE LIPID METABOLISM | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |